BBIO

BridgeBio Pharma, Inc. [BBIO] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BBIO Stock Summary

Top 10 Correlated ETFs

BBIO


Top 10 Correlated Stocks

BBIO


In the News

02:33 29 Mar 2024 BBIO

BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe

BridgeBio Pharma has granted German drugmaker Bayer an exclusive license to commercialize its heart disease drug in Europe, the companies said on Monday.

02:30 29 Mar 2024 BBIO

BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?

Bayer snagged commercial rights to BridgeBio's lead asset, acoramidis, in Europe for $310 million. BridgeBio stock is nearing a breakout.

09:41 29 Mar 2024 BBIO

BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.87 per share a year ago.

11:06 29 Mar 2024 BBIO

Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

12:35 29 Mar 2024 BBIO

3 Groundbreaking Biotech Stocks to Invest in Now

Biotechnology companies are intriguing investment vehicles because they are part of a pretty speculative industry that allows investors to grow their investments rapidly — if they pick a company before it releases positive results. But on the flip side, a single negative press release could send a stock tumbling with biotech stocks being so volatile.

05:19 29 Mar 2024 BBIO

BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck

BridgeBio Pharma, Inc. expects results from the phase 1/2 study, using gene therapy BBP-631 for the treatment of patients with congenital adrenal hyperplasia, in early 2024. The congenital adrenal hyperplasia treatment market is expected to reach $892 million by 2033. Potential FDA acceptance of regulatory application of acromidis for the treatment of patients with ATTR-CM, expected within 60 days after submission achieved December 5th of 2023.

03:18 29 Mar 2024 BBIO

BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner

BridgeBio's FDA filing for acoramidis and advances in KRAS mutation cancer treatment contrast with growing financial losses. Acoramidis competes with Pfizer's ATTR-CM treatments; BBIO's oncology focus includes promising KRAS inhibitors and RAS-targeting strategies. Financially, the Company reports increased net loss and share count, yet possesses a solid short-term solvency with high long-term debts.

06:45 29 Mar 2024 BBIO

2 Biotechs That Could Get Bought Out in 2024

With several big pharmas set to lose patent protection for key drugs this decade, the merger and acquisition scene is widely expected to heat up in 2024. These two biotechs have repeatedly been rumored to be receiving takeover interest from larger peers.

05:34 29 Mar 2024 BBIO

3 Russell 2000 Stocks That Are About to Get Absolutely Crushed

For most of the year, the Russell 2000 has lagged far behind its peers, the S&P500 and the Nasdaq. However, the small-to-mid cap index appears to be closing the gap.

07:30 29 Mar 2024 BBIO

BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023

PALO ALTO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that additional Phase 3 data on clinical outcomes from ATTRibute-CM, its study of acoramidis in ATTR-CM will be presented at the AHA Scientific Sessions 2023, taking place in Philadelphia, Pennsylvania on November 11 - 13, 2023. As previously announced, a highly statistically significant result was observed on the primary endpoint of ATTRibute-CM with a Win Ratio of 1.8 (p

BBIO Financial details

Company Rating
Sell
Market Cap
5.46B
Income
-679.89M
Revenue
9.3M
Book val./share
-7.76
Cash/share
2.49
Dividend
-
Dividend %
-
Employees
550
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-9.72
Forward P/E
-9.77
PEG
-3.92
P/S
733.1
P/B
-5.37
P/C
12.32
P/FCF
-13.88
Quick Ratio
5.01
Current Ratio
5.39
Debt / Equity
-1.28
LT Debt / Equity
-1.29
-
-
EPS (TTM)
-4.18
EPS next Y
-3.14
EPS next Q
-0.92
EPS this Y
-99.88%
EPS next Y
-24.79%
EPS next 5Y
-181.94%
EPS last 5Y
-72.36%
Revenue last 5Y
-25.51%
Revenue Q/Q
-57.35%
EPS Q/Q
-11.11%
-
-
-
-
SMA20
-11.76%
SMA50
-21.05%
SMA100
15.38%
Inst Own
87.26%
Inst Trans
0.9%
ROA
-102%
ROE
53%
ROC
-1%
Gross Margin
74%
Oper. Margin
-5856%
Profit Margin
-7082%
Payout
-
Shs Outstand
184.45M
Shs Float
136.57M
-
-
-
-
Target Price
18
52W Range
12.75-44.32
52W High
-30.31%
52W Low
+155.54%
RSI
51
Rel Volume
0.46
Avg Volume
1.82M
Volume
842.19K
Perf Week
7.11%
Perf Month
-21.83%
Perf Quarter
21.4%
Perf Half Y
13.24%
-
-
-
-
Beta
1.046
-
-
Volatility
0.71%, 2.95%
Prev Close
-0.63%
Price
30.665
Change
0.57%

BBIO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.390.070.480.530
Net income per share
-2.48-4.1-4.43-3.350
Operating cash flow per share
-2.41-3.39-3.45-2.840
Free cash flow per share
-2.46-3.45-3.78-2.890
Cash per share
5.25.155.83.20
Book value per share
3.890.49-6.03-8.51-0.01
Tangible book value per share
4.530.91-6.31-8.64-0.01
Share holders equity per share
3.890.49-6.03-8.51-0.01
Interest debt per share
1.114.5112.3212.260.01
Market cap
3.68B8.39B2.41B1.12B6571.89B
Enterprise value
3.42B8.53B3.74B2.47B6573.26B
P/E ratio
-14.14-17.34-3.77-2.27-10.22K
Price to sales ratio
90.821.02K34.5414.47706.43K
POCF ratio
-14.53-20.99-4.84-2.68-12.45K
PFCF ratio
-14.24-20.6-4.41-2.64-12.42K
P/B Ratio
9.02144.9-2.77-0.9-4.85K
PTB ratio
9.02144.9-2.77-0.9-4.85K
EV to sales
84.311.03K53.6531.82706.57K
Enterprise value over EBITDA
-12.24-18.19-6.93-6.99-11.44K
EV to operating cash flow
-13.49-21.34-7.51-5.89-12.46K
EV to free cash flow
-13.22-20.95-6.85-5.8-12.43K
Earnings yield
-0.07-0.06-0.27-0.440
Free cash flow yield
-0.07-0.05-0.23-0.380
Debt to equity
0.268.56-1.99-1.38-1.28
Debt to assets
0.170.71.712.773.18
Net debt to EBITDA
0.94-0.3-2.47-3.81-2.37
Current ratio
11.4576.454.293.32
Interest coverage
-30.38-12.94-12.39-5.87-7.47
Income quality
0.880.790.850.870.81
Dividend Yield
00.06000
Payout ratio
0-1.11-0.0100
Sales general and administrative to revenue
2.3317.66000
Research and developement to revenue
5.1840.866.515.1948.99
Intangibles to total assets
000.040.050.05
Capex to operating cash flow
0.020.020.10.020
Capex to revenue
-0.13-0.91-0.69-0.08-0.14
Capex to depreciation
-5.98-2.43-8.26-0.93-0.2
Stock based compensation to revenue
0.537.091.431.1811.69
Graham number
14.726.7324.5125.320.03
ROIC
-0.46-0.79-0.72-0.98-1.69
Return on tangible assets
-0.41-0.69-0.66-0.83-1.24
Graham Net
3.710.1-7.35-9.25-0.01
Working capital
547.38M550.97M709.58M387.45M333.75M
Tangible asset value
475.98M107.89M-910.51M-1.27B-1.37B
Net current asset value
444.06M47.12M-1.04B-1.36B-1.41B
Invested capital
0.268.56-1.99-1.38-1.28
Average receivables
009.87M18.41M9.42M
Average payables
11.18M8.9M10.41M11.72M11.11M
Average inventory
00-34.45M-15.48M27.29M
Days sales outstanding
00103.480.2868.7
Days payables outstanding
1.29K1.06K1.39K1.23K1.59K
Days of inventory on hand
00-8.08K4.03K2.49K
Receivables turnover
003.534.555.31
Payables turnover
0.280.350.260.30.23
Inventory turnover
00-0.050.090.15
ROE
-0.64-8.360.730.390.47
Capex per share
-0.05-0.06-0.33-0.040

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.010.010.010.030.01
Net income per share
-1.04-1.16-0.98-1.08-0.96
Operating cash flow per share
-0.62-0.95-0.71-0.89-0.72
Free cash flow per share
-0.63-0.95-0.71-0.89-0.72
Cash per share
3.162.893.963.332.49
Book value per share
-8.4-8.03-8.48-7.39-7.76
Tangible book value per share
-8.53-8.13-8.58-7.47-7.85
Share holders equity per share
-8.4-8.03-8.48-7.39-7.76
Interest debt per share
11.711.4810.9510.5310.09
Market cap
1.14B2.53B2.76B4.31B7.04B
Enterprise value
2.48B3.85B4.19B5.54B8.41B
P/E ratio
-1.82-3.58-4.37-6.08-10.47
Price to sales ratio
608.561.39K1.68K1.05K4.04K
POCF ratio
-12.2-17.54-24.36-29.65-56.43
PFCF ratio
-12.1-17.53-24.27-29.57-56.23
P/B Ratio
-0.91-2.06-2.03-3.57-5.2
PTB ratio
-0.91-2.06-2.03-3.57-5.2
EV to sales
1.33K2.11K2.55K1.35K4.82K
Enterprise value over EBITDA
-22.01-32.76-31.07-35.11-49.68
EV to operating cash flow
-26.65-26.69-36.99-38.12-67.35
EV to free cash flow
-26.42-26.69-36.85-38.01-67.12
Earnings yield
-0.14-0.07-0.06-0.04-0.02
Free cash flow yield
-0.08-0.06-0.04-0.03-0.02
Debt to equity
-1.38-1.41-1.28-1.44-1.28
Debt to assets
2.772.773.452.663.18
Net debt to EBITDA
-11.93-11.24-10.61-7.8-8.06
Current ratio
4.295.413.65.393.32
Interest coverage
-6.11-6.27-7.097.77-8.75
Income quality
0.661.010.710.810.73
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
48.9651.2165.8730.5974.63
Intangibles to total assets
0.050.040.050.040.05
Capex to operating cash flow
0.010000
Capex to revenue
-0.43-0.01-0.26-0.11-0.25
Capex to depreciation
-0.48-0.01-0.26-0.26-0.27
Stock based compensation to revenue
11.651216.565.5221.22
Graham number
14.0514.4713.713.4312.97
ROIC
-0.28-0.3-0.42-0.29-0.49
Return on tangible assets
-0.26-0.3-0.33-0.28-0.32
Graham Net
-9.14-9.02-7.48-7.92-8.28
Working capital
387.45M409.98M276.05M447.69M333.75M
Tangible asset value
-1.27B-1.24B-1.38B-1.22B-1.37B
Net current asset value
-1.36B-1.34B-1.47B-1.3B-1.41B
Invested capital
-1.38-1.41-1.28-1.44-1.28
Average receivables
20.83M13.92M9.69M6.89M3.46M
Average payables
10.86M7.82M3.98M4.17M7.56M
Average inventory
18.97M31.72M22.72M18.29M16.65M
Days sales outstanding
821.98530.39472.43113.7490.31
Days payables outstanding
1.61K563.5582.07673.041.6K
Days of inventory on hand
5.28K3.53K2.99K2.51K2.51K
Receivables turnover
0.110.170.190.791
Payables turnover
0.060.160.150.130.06
Inventory turnover
0.020.030.030.040.04
ROE
0.120.140.120.150.12
Capex per share
-0.010000

BBIO Frequently Asked Questions

What is BridgeBio Pharma, Inc. stock symbol ?

BridgeBio Pharma, Inc. is a US stock , located in Palo alto of Ca and trading under the symbol BBIO

Is BridgeBio Pharma, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $18. The lowest prediction is $17 and the highest is $19

What is BBIO stock prediction ?

What is BridgeBio Pharma, Inc. stock quote today ?

BridgeBio Pharma, Inc. stock price is $30.665 today.

Is BridgeBio Pharma, Inc. stock public?

Yes, BridgeBio Pharma, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap